Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A soars ^60.2%

STAT - By Allison DeAngelis - 7/6/2026, 8:52 PM

Anchoring Bias 34.5% - Optimism Bias 32.7% - Halo Effect 32.7%

Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder, the companies announced Monday. Through the deal, Vertex will pick up Crinetics’ commercial drug, Palsonify, which was launched last year and which treats a rare endocrine disorder called acromegaly, as well as... more